EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread. The FDA will now decide on Exelixis’s new application by March 3, 2027. A March decision would push a possible U.S. launch out of this year … Read more